12,372 trials
Chronic Plaque Psoriasis · Moderate to Severe Chronic Plaque Psoriasis
Primary: Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Investigational Medicinal Product (IMP) — 97.83; 179.68; 79.02; 77.11 no…
SARS-CoV-2 Infection · COVID-19 · Maternal Immunization
Primary: Percentage of Maternal Participants Reporting Local Reactions Within 7 Days After Dose 1 — 2.5; 0.6; 0.6; 0 Percentage of participants
Parkinson Disease · Orthostatic Hypotension
Primary: Change in Systolic Blood Pressure From Supine to Tilt at 3 Minutes — -24.22; -20.32 mmHg
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Egg Reduction Rate Against T. Trichiura — 96.8; 99.0; 86.2; 94.2 Percent change
Immunization Against COVID-19
Primary: The Number of Laboratory-confirmed SARS-CoV-2 Infections. — 7; 22 Participants — p=0.0046
Crohn Disease
Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Score < 150 — 29.8; 30.5 percentage of participants — p=0.8125
Platysma Prominence
Primary: Number of Participants With Adverse Events — 33; 74; 46; 26 Participants
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 — 32.2; 53.8; 52.0 percentage of…
Osteoporosis
Primary: Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine to the End of Double-Blind Period — 0.44; 9.81 percent change — p=<0.001
Dry Eye Disease
Primary: Number of Patients With Schirmer I Test (Without Anesthesia) >10mm/5min in the Eligible Eye at Week 4 — 19; 4 Participants — p=0.002
Diabetes Mellitus, Type 2
Primary: Change in Glycated Haemoglobin (HbA1c) — -1.57; -1.36 Percentage of HbA1c — p=<0.0001
Cardiomyopathy, Hypertrophic Obstructive
Primary: Change From Baseline in Post-exercise Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30 — -60.6963 millimeters of mercury (mmHg)
Primary IgA Nephropathy
Primary: Part A: Ratio of Urine Protein to Creatinine Ratio (UPCR) at 9 Months Compared to Baseline — 0.69; 0.95 ratio — p=0.0003
Papulopustular Rosacea
Primary: Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo. — 74; 22 Participants
Papulopustular Rosacea
Primary: Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo. — 79; 25 Participants